Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Receivables - Other: 2020-2024

Historic Receivables - Other for Kymera Therapeutics (KYMR) over the last 5 years, with Dec 2024 value amounting to $947,000.

  • Kymera Therapeutics' Receivables - Other rose 885.22% to $20.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $20.0 million, marking a year-over-year increase of 885.22%. This contributed to the annual value of $947,000 for FY2024, which is 75.08% down from last year.
  • Kymera Therapeutics' Receivables - Other amounted to $947,000 in FY2024, which was down 75.08% from $3.8 million recorded in FY2023.
  • Over the past 5 years, Kymera Therapeutics' Receivables - Other peaked at $3.8 million during FY2023, and registered a low of $135,000 during FY2021.
  • Over the past 3 years, Kymera Therapeutics' median Receivables - Other value was $2.5 million (recorded in 2022), while the average stood at $2.4 million.
  • As far as peak fluctuations go, Kymera Therapeutics' Receivables - Other tumbled by 84.23% in 2021, and later surged by 1,779.26% in 2022.
  • Yearly analysis of 5 years shows Kymera Therapeutics' Receivables - Other stood at $856,000 in 2020, then slumped by 84.23% to $135,000 in 2021, then spiked by 1,779.26% to $2.5 million in 2022, then soared by 49.78% to $3.8 million in 2023, then slumped by 75.08% to $947,000 in 2024.